Obermatt
See Similar Stocks →

Boiron

PAR:BOI · FR0000061129
PharmaceuticalsSmall

360

89
Medium confidence — indicative
EV / EBIT69
Price / Owner Earnings19
Owner Earnings Yield73
Dividend Yield1
Price/Sales92
EV / Gross Profit94
Price/Book93
Return on Capital85
Cash Return on Capital75
Return on Equity67
EBIT Margin65
Gross Profitability96
Cash Conversion73
Accruals53
Owner Earnings Margin57
Sales growth45
Profit Growth93
Long-Term EPS Growth40
Owner Earnings Growth56
Reinvestment44
Price momentum60
Debt load75
Refinancing92
Debt Payback100
Liquidity84
Analyst ratings7
Expectations trend50
Market mood4
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Boiron clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryFrance
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeENXTPA
Employees1,017
Websiteboiron.fr
ISINFR0000061129
Last UpdateApr 2, 2026
Index & Theme
NutraceuticalAlternative MedicineWellness and RecoveryHealth DiagnosticsPain ManagementAllergy

Description

Boiron SA is a leading manufacturer and marketer of homeopathic medicines and healthcare solutions. Business Segments The company operates primarily in a singular segment: the manufacture and marketing of homeopathic medicines and other healthcare…

Analysis

Hidden champion

Boiron SA is what we call a hidden champion: a strong business that the market is not pricing as one.

The price is attractive. You pay 13.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2023202420252026

All-time high

94

Jun 2026

All-time low

58

Jan 2023

Average rank

78

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
92
80
76
87
Price/Earnings
86
84
62
80
Price/Book
93
86
83
90
Dividend Yield
1
96
82
92
Value (overall)
87
96
89
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Boiron with its peers
Laboratorios Farmaceuticos Rovi
MCE:ROVI
46
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
GlaxoSmithKline Pharmaceuticals
NSI:GLAXO
53
CountryUK
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Faes Farma
MCE:FAE
44
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Avadel Pharmaceuticals
NMQ:AVDL
70
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →